Arensia Clinics S.R.L.
- Address
- Intrarea Tudor Stefan 38-40, 011658 Bucharest, Romania
Arensia Clinics S.R.L. - Multi-Specialty Clinical Research Center
Arensia Clinics S.R.L. is a comprehensive clinical research facility specializing in early-phase through late-phase clinical trials across multiple therapeutic domains. The center demonstrates particular expertise in immunological disorders, oncology, and autoimmune diseases, conducting sophisticated studies that evaluate both novel investigational agents and biosimilar candidates. Their research portfolio spans from pharmacokinetic comparability studies to complex efficacy trials in challenging disease populations.
- Autoimmune and inflammatory conditions including rheumatoid arthritis, Sjögren's syndrome, alopecia areata, and bullous pemphigoid
- Respiratory diseases with focus on moderate-to-severe uncontrolled asthma and high-risk asthma populations
- Oncology and hematologic malignancies including melanoma and relapsed/refractory B-cell blood cancers
- Neurological disorders, metabolic conditions including obesity management, and gastroenterological diseases such as ulcerative colitis
The center's capabilities extend to conducting biosimilar comparability trials for complex biologics, including studies in relapsing-remitting multiple sclerosis, as well as first-in-human Phase 1 studies evaluating safety, tolerability, and pharmacodynamics of novel therapeutic candidates. With experience in cardiovascular and renal disease research, including chronic kidney disease with atherosclerotic cardiovascular complications, Arensia Clinics demonstrates the infrastructure and expertise necessary to manage diverse patient populations and complex study designs requiring rigorous safety monitoring and advanced pharmacometric assessments.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 8 therapeutic areas and 15 of 20 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 17 by active trials.
- 1Novartis Pharma AG3active
lock +16 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Novartis Pharma AG3trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 442 other sites in Romania
Therapeutic Area Benchmark — Romania
Select a therapeutic area to compare against other sites in Romania.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Romania
Market Share
Country: Romania
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Arensia Clinics S.R.L.
lock Showing 1 of 35 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Double-blind, Randomized, Active-controlled, Parallel-group, Phase 1/3 study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients with Relapsing-remitting Multiple Sclerosis. | Celltrion Inc. | Phase III | Not Recruiting | Jan 2024 | — |
IMP list
lock Showing 1 of 20 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ocrelizumab | 2 | Unknown | 2024-01-16 | 2025-09-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.